NO321548B1 - Monoklonalt antistoff som binder seg til GA733-1-antigen, hybridom, konjugat, humant/muse-rekombinant antistoff, nukleinsyremolekyl, plasmid, vertsvektorsystem samt fremgangsmate for fremstilling av et protein. - Google Patents
Monoklonalt antistoff som binder seg til GA733-1-antigen, hybridom, konjugat, humant/muse-rekombinant antistoff, nukleinsyremolekyl, plasmid, vertsvektorsystem samt fremgangsmate for fremstilling av et protein. Download PDFInfo
- Publication number
- NO321548B1 NO321548B1 NO19981745A NO981745A NO321548B1 NO 321548 B1 NO321548 B1 NO 321548B1 NO 19981745 A NO19981745 A NO 19981745A NO 981745 A NO981745 A NO 981745A NO 321548 B1 NO321548 B1 NO 321548B1
- Authority
- NO
- Norway
- Prior art keywords
- antibody
- antigen
- cells
- monoclonal antibody
- human
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US564195P | 1995-10-19 | 1995-10-19 | |
| PCT/US1996/016070 WO1997014796A1 (en) | 1995-10-19 | 1996-10-07 | Monoclonal antibody br110 and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO981745D0 NO981745D0 (no) | 1998-04-17 |
| NO981745L NO981745L (no) | 1998-04-17 |
| NO321548B1 true NO321548B1 (no) | 2006-05-29 |
Family
ID=21716930
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19981745A NO321548B1 (no) | 1995-10-19 | 1998-04-17 | Monoklonalt antistoff som binder seg til GA733-1-antigen, hybridom, konjugat, humant/muse-rekombinant antistoff, nukleinsyremolekyl, plasmid, vertsvektorsystem samt fremgangsmate for fremstilling av et protein. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US5840854A (de) |
| EP (1) | EP0856054B1 (de) |
| JP (1) | JP2001501801A (de) |
| AT (1) | ATE265532T1 (de) |
| AU (1) | AU7394296A (de) |
| CA (1) | CA2235269C (de) |
| DE (1) | DE69632333T2 (de) |
| ES (1) | ES2219699T3 (de) |
| IL (1) | IL123294A0 (de) |
| NO (1) | NO321548B1 (de) |
| WO (1) | WO1997014796A1 (de) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7354587B1 (en) * | 1994-07-06 | 2008-04-08 | Immunomedics, Inc. | Use of immunoconjugates to enhance the efficacy of multi-stage cascade boosting vaccines |
| US6136311A (en) | 1996-05-06 | 2000-10-24 | Cornell Research Foundation, Inc. | Treatment and diagnosis of cancer |
| US6366762B1 (en) * | 1999-03-31 | 2002-04-02 | Qualcomm, Inc. | System and method for measuring round trip delay on the paging and access channels |
| US6617432B1 (en) * | 1999-10-15 | 2003-09-09 | University Of Pittsburgh | Nuclear matrix proteins polynucleotide sequences encoding them and their use |
| US20030009781A1 (en) * | 2001-03-29 | 2003-01-09 | Allen Keith D. | Transgenic mice containing Kir3.3 potassium channel gene disruptions |
| US20020155109A1 (en) * | 2001-04-20 | 2002-10-24 | Lynch David H. | Bispecific antibodies that bind TRAIL-R1 and TRAIL-R2 |
| US8435529B2 (en) | 2002-06-14 | 2013-05-07 | Immunomedics, Inc. | Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy |
| US9745380B2 (en) * | 2002-03-01 | 2017-08-29 | Immunomedics, Inc. | RS7 antibodies |
| US9770517B2 (en) | 2002-03-01 | 2017-09-26 | Immunomedics, Inc. | Anti-Trop-2 antibody-drug conjugates and uses thereof |
| CA2478047C (en) | 2002-03-01 | 2014-01-21 | Immunomedics, Inc. | Rs7 antibodies |
| US9701754B1 (en) | 2002-10-23 | 2017-07-11 | City Of Hope | Covalent disulfide-linked diabodies and uses thereof |
| US20080305104A1 (en) * | 2006-02-24 | 2008-12-11 | Young David S F | Cytotoxicity mediation of cells evidencing surface expression of TROP-2 |
| US20080131428A1 (en) * | 2006-02-24 | 2008-06-05 | Arius Research, Inc. | Cytotoxicity mediation of cells evidencing surface expression of TROP-2 |
| US20080213267A1 (en) * | 2006-02-24 | 2008-09-04 | Arius Research, Inc. | Cytotoxicity mediation of cells evidencing surface expression of TROP-2 |
| US7420040B2 (en) * | 2006-02-24 | 2008-09-02 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of TROP-2 |
| CA2646329C (en) | 2006-03-20 | 2018-07-03 | The Regents Of The University Of California | Engineered anti-prostate stem cell antigen (psca) antibodies for cancer targeting |
| JP4689521B2 (ja) * | 2006-04-07 | 2011-05-25 | 財団法人電力中央研究所 | 抗鉛モノクローナル抗体 |
| WO2009032949A2 (en) | 2007-09-04 | 2009-03-12 | The Regents Of The University Of California | High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection |
| ES2712732T3 (es) | 2009-02-17 | 2019-05-14 | Cornell Res Foundation Inc | Métodos y kits para el diagnóstico de cáncer y la predicción de valor terapéutico |
| AU2010325969B2 (en) | 2009-12-02 | 2016-10-20 | Imaginab, Inc. | J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen |
| EA201500220A1 (ru) | 2010-05-17 | 2015-10-30 | Ливтех, Инк. | Антитело против trop-2 человека, обладающее противоопухолевой активностью in vivo |
| WO2011155579A1 (ja) * | 2010-06-10 | 2011-12-15 | 北海道公立大学法人札幌医科大学 | 抗Ｔｒｏｐ－２抗体 |
| TWI495644B (zh) | 2011-11-11 | 2015-08-11 | Rinat Neuroscience Corp | 營養層細胞表面抗原（Ｔｒｏｐ－２）之專一性抗體類及彼等之用途 |
| US9427464B2 (en) | 2011-11-22 | 2016-08-30 | Chiome Bioscience Inc. | Anti-human TROP-2 antibody having an antitumor activity in vivo |
| JP6447933B2 (ja) | 2014-02-21 | 2019-01-09 | アイビーシー ファーマスーティカルズ，インコーポレイテッド | Ｔｒｏｐ−２発現細胞に対する免疫応答を誘発することによる疾患治療 |
| AU2016252771B2 (en) | 2015-04-22 | 2021-12-16 | Immunomedics, Inc. | Isolation, detection, diagnosis and/or characterization of circulating Trop-2-positive cancer cells |
| US11254744B2 (en) | 2015-08-07 | 2022-02-22 | Imaginab, Inc. | Antigen binding constructs to target molecules |
| US11266745B2 (en) | 2017-02-08 | 2022-03-08 | Imaginab, Inc. | Extension sequences for diabodies |
| CN113260384A (zh) | 2018-11-05 | 2021-08-13 | 西纳福克斯股份有限公司 | 用于靶向表达trop-2的肿瘤的抗体缀合物 |
| AU2021240037A1 (en) | 2020-03-20 | 2022-09-22 | Immunomedics, Inc. | Biomarkers for sacituzumab govitecan therapy |
| CN116234573A (zh) | 2020-10-14 | 2023-06-06 | 上海翰森生物医药科技有限公司 | 抗trop-2抗体、其抗原结合片段或其突变体、及其医药用途 |
| CN117295524A (zh) | 2021-06-02 | 2023-12-26 | 百奥泰生物制药股份有限公司 | 药物偶联物及其用途 |
| CA3232425A1 (en) | 2021-09-23 | 2023-03-30 | Shanghai Hansoh Biomedical Co., Ltd. | Antibody-drug conjugate, preparation method therefor, and pharmaceutical use thereof |
| CA3253220A1 (en) | 2022-03-23 | 2023-09-28 | Synaffix B.V. | ANTIBODIES CONJUGATED FOR TARGETING TUMORS EXPRESSING TROP-2 |
| US20250381283A1 (en) | 2022-06-27 | 2025-12-18 | Bio-Thera Solutions, Ltd. | Method for treating solid tumor |
| EP4701667A1 (de) | 2023-04-24 | 2026-03-04 | Merck Sharp & Dohme LLC | Trop2-bindemittel und konjugate davon |
| WO2025019790A1 (en) | 2023-07-19 | 2025-01-23 | Iovance Biotherapeutics, Inc. | Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with trop-2 targeting adc |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5185254A (en) * | 1988-12-29 | 1993-02-09 | The Wistar Institute | Gene family of tumor-associated antigens |
| ES2091824T3 (es) * | 1989-04-21 | 1996-11-16 | Us Health | Proteina recombinante de fusion toxina anticuerpo. |
| WO1993008298A1 (en) * | 1991-10-18 | 1993-04-29 | The Wistar Institute Of Anatomy And Biology | Soluble variants of type i membrane proteins, and methods of using them |
-
1996
- 1996-10-07 EP EP96936244A patent/EP0856054B1/de not_active Expired - Lifetime
- 1996-10-07 AT AT96936244T patent/ATE265532T1/de not_active IP Right Cessation
- 1996-10-07 AU AU73942/96A patent/AU7394296A/en not_active Abandoned
- 1996-10-07 WO PCT/US1996/016070 patent/WO1997014796A1/en not_active Ceased
- 1996-10-07 IL IL12329496A patent/IL123294A0/xx unknown
- 1996-10-07 DE DE69632333T patent/DE69632333T2/de not_active Expired - Fee Related
- 1996-10-07 CA CA002235269A patent/CA2235269C/en not_active Expired - Fee Related
- 1996-10-07 JP JP09515854A patent/JP2001501801A/ja not_active Ceased
- 1996-10-07 ES ES96936244T patent/ES2219699T3/es not_active Expired - Lifetime
- 1996-10-07 US US08/726,528 patent/US5840854A/en not_active Expired - Fee Related
-
1998
- 1998-04-17 NO NO19981745A patent/NO321548B1/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO1997014796A1 (en) | 1997-04-24 |
| DE69632333D1 (de) | 2004-06-03 |
| EP0856054B1 (de) | 2004-04-28 |
| MX9802129A (es) | 1998-05-31 |
| CA2235269C (en) | 2006-09-19 |
| NO981745D0 (no) | 1998-04-17 |
| EP0856054A1 (de) | 1998-08-05 |
| IL123294A0 (en) | 1998-09-24 |
| ES2219699T3 (es) | 2004-12-01 |
| JP2001501801A (ja) | 2001-02-13 |
| US5840854A (en) | 1998-11-24 |
| DE69632333T2 (de) | 2004-12-30 |
| CA2235269A1 (en) | 1997-04-24 |
| AU7394296A (en) | 1997-05-07 |
| NO981745L (no) | 1998-04-17 |
| ATE265532T1 (de) | 2004-05-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0856054B1 (de) | Monoklonaler antikörper br110 und dessen anwendung | |
| AU773568B2 (en) | Antobody to human gastrointestinal epithelial tumor antigen related to alpha 6 beta 4 integrin | |
| JP6110321B2 (ja) | 細胞表面の前立腺特異的膜抗原に対するモノクローナル抗体および単鎖抗体フラグメント | |
| US5792456A (en) | Mutant BR96 antibodies reactive with human carcinomas | |
| AU2012331069B2 (en) | Antigen binding protein and its use as addressing product for the treatment cancer | |
| CN109320612B (zh) | 抗her2抗体及其缀合物 | |
| Mazor et al. | Antibody internalization studied using a novel IgG binding toxin fusion | |
| EP0590067A1 (de) | Mikrobiell hergestellte antikörper-fragmente und deren konjugate | |
| CN107488230A (zh) | 一种抗人CD79a胞外端蛋白的抗体、编码基因及应用 | |
| CN115505043A (zh) | 特异性结合糖基化ceacam5的抗体 | |
| US20160017034A1 (en) | Composition for treatment and diagnosis of pancreatic cancer | |
| US6787638B1 (en) | Tumor specific human monoclonal antibodies and methods of use | |
| US5728821A (en) | Mutant BR96 antibodies reactive with human carcinomas | |
| MXPA98002129A (en) | Monoclonal antibody br110 and uses of the mi | |
| EP4635983A1 (de) | Neuartiger antikörper mit spezifischer bindung an nptxr und verwendung davon | |
| US20240101680A1 (en) | Antibodies Targeting Integrin Beta-2 | |
| WO2026044399A1 (en) | Antibodies targeting central nervous system localized antigens | |
| EP4702055A1 (de) | Bindungsmolekül gegen p95 her2-varianten | |
| CN118063613A (zh) | 一种靶向trop2和cd3的双特异性抗体及其制备方法与应用 | |
| HK1197073B (en) | Antigen binding protein and its use as addressing product for the treatment of cancer |